CY1113522T1 - Συνδυασμενα εμβολια μηνιγγιτιδας - Google Patents

Συνδυασμενα εμβολια μηνιγγιτιδας

Info

Publication number
CY1113522T1
CY1113522T1 CY20111100726T CY111100726T CY1113522T1 CY 1113522 T1 CY1113522 T1 CY 1113522T1 CY 20111100726 T CY20111100726 T CY 20111100726T CY 111100726 T CY111100726 T CY 111100726T CY 1113522 T1 CY1113522 T1 CY 1113522T1
Authority
CY
Cyprus
Prior art keywords
miningitis
vaccines
combined
addition
activity against
Prior art date
Application number
CY20111100726T
Other languages
Greek (el)
English (en)
Inventor
Mario Contorni
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34424891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113522(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0323102A external-priority patent/GB0323102D0/en
Priority claimed from GB0412052A external-priority patent/GB0412052D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1113522T1 publication Critical patent/CY1113522T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CY20111100726T 2003-10-02 2011-07-22 Συνδυασμενα εμβολια μηνιγγιτιδας CY1113522T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0323102A GB0323102D0 (en) 2003-10-02 2003-10-02 Liquid vaccines for multiple meningococcal serogroups
GB0412052A GB0412052D0 (en) 2004-05-28 2004-05-28 Liquid vaccines for multiple meningococcal serogroups
EP08075538A EP1961426B1 (en) 2003-10-02 2004-10-04 Combined meningitis vaccines

Publications (1)

Publication Number Publication Date
CY1113522T1 true CY1113522T1 (el) 2016-06-22

Family

ID=34424891

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100726T CY1113522T1 (el) 2003-10-02 2011-07-22 Συνδυασμενα εμβολια μηνιγγιτιδας
CY20131100121T CY1113888T1 (el) 2003-10-02 2013-02-08 Υγρα εμβολια για πολλαπλες μηνιγγιτιδοκοκκικες οροομαδες

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20131100121T CY1113888T1 (el) 2003-10-02 2013-02-08 Υγρα εμβολια για πολλαπλες μηνιγγιτιδοκοκκικες οροομαδες

Country Status (18)

Country Link
US (2) US8765135B2 (OSRAM)
EP (3) EP2277538A1 (OSRAM)
JP (3) JP4738339B2 (OSRAM)
CN (2) CN103405761A (OSRAM)
AT (1) ATE506963T1 (OSRAM)
AU (2) AU2004277758A1 (OSRAM)
BR (2) BRPI0415025A (OSRAM)
CA (2) CA2885040C (OSRAM)
CY (2) CY1113522T1 (OSRAM)
DE (1) DE602004032481D1 (OSRAM)
DK (2) DK1961426T3 (OSRAM)
ES (1) ES2397923T3 (OSRAM)
NZ (1) NZ546430A (OSRAM)
PL (2) PL1961426T3 (OSRAM)
PT (2) PT1670506E (OSRAM)
RU (2) RU2378010C2 (OSRAM)
SI (2) SI1961426T1 (OSRAM)
WO (1) WO2005032583A2 (OSRAM)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1093517T3 (da) * 1998-05-01 2008-06-23 Novartis Vaccines & Diagnostic Neisseria-meningitidis-antigener og præparater
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
PT1741443E (pt) 1998-05-29 2014-07-31 Novartis Vaccines & Diagnostic Combinação de vacinas para a meningite b/c
NZ530640A (en) 1999-04-30 2006-06-30 Chiron S Conserved neisserial antigens
NZ515935A (en) 1999-05-19 2004-01-30 Chiron S Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis
EP2275553B1 (en) 1999-10-29 2015-05-13 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigenic peptides
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CA2871789C (en) * 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
JP4763210B2 (ja) * 2000-02-28 2011-08-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ナイセリアのタンパク質の異種発現
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US20050232936A1 (en) 2001-07-27 2005-10-20 Chiron Corporation Meningococcus adhesins nada, app and orf 40
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2489030A1 (en) * 2002-08-02 2004-02-19 Glaxosmithkline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
MXPA05003863A (es) 2002-10-11 2005-09-08 Chiron Srl Vacunas polipeptidicas para amplia proteccion contra lineas hipervirulentas de meningococos.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ES2397923T3 (es) * 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
AU2011204789B2 (en) * 2004-04-22 2013-07-11 Glaxosmithkline Biologicals S.A. Immunising against meningococcal serogroup Y using proteins
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
AU2012203419B2 (en) * 2005-06-27 2014-06-26 Glaxosmithkline Biologicals S.A. Immunogenic composition
KR101359953B1 (ko) * 2005-06-27 2014-02-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
CA2632434A1 (en) * 2005-12-06 2007-06-14 Universita Degli Studi Di Padova Methods and compositions relating to adhesins as adjuvants
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2008149238A2 (en) 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
EP2462949A3 (en) * 2007-10-19 2012-09-05 Novartis AG Meningococcal vaccine formulations
NZ587382A (en) 2008-02-21 2012-01-12 Novartis Ag Meningococcal fhbp polypeptides
US20100035234A1 (en) * 2008-05-19 2010-02-11 Novartis Ag Vaccine assays
EP2294085A1 (en) * 2008-06-09 2011-03-16 Novartis AG Antibodies against neisserial factor h binding protein
GB0816447D0 (en) 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
US20110020392A1 (en) * 2008-10-14 2011-01-27 Salubrious Pharmaceutical, Llc Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers
US20100330117A1 (en) * 2008-09-26 2010-12-30 Salubrious Pharmaceutical, Llc Process for treatment of amyotrophic lateral sclerosis, rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis, non-viral based cancers, alzheimers's disease, muscular dystrophy, attention deficit disorder, attention deficit hyperactivity disorder, complex regional pain syndrome, diabetes, neuropathic pain, spider arthritis, west nile virus, fibromyalgia, shingles, gout, migraine headaches, senile dementia, post polio syndrome, central virus deafness, asthma, chronic pain of unknown origin and hepatitis c
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
DK2608805T4 (da) 2010-08-23 2025-06-30 Wyeth Llc STABILE FORMULERINGER AF NEISSERIA MENINGITIDIS rLP2086 ANTIGENER
EP2612148B1 (en) 2010-09-04 2019-06-12 GlaxoSmithKline Biologicals SA Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
SG11201404447WA (en) * 2012-01-30 2014-08-28 Serum Inst India Ltd Immunogenic composition
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
PE20190458A1 (es) 2012-03-09 2019-04-01 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas
JP5698693B2 (ja) * 2012-03-13 2015-04-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 髄膜炎菌特異的抗血清に対する血清殺菌アッセイ
WO2013186753A1 (en) 2012-06-14 2013-12-19 Novartis Ag Vaccines for serogroup x meningococcus
CA2875391A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2016091902A1 (en) * 2014-12-09 2016-06-16 Sanofi Pasteur Compositions comprising n. meningitidis proteins
MX391027B (es) 2015-02-19 2025-03-21 Pfizer Composiciones de neisseria meningitidis y metodos de la misma.
US10374088B2 (en) * 2015-06-16 2019-08-06 International Business Machines Corporation Low parasitic capacitance and resistance finFET device
WO2017017509A1 (en) * 2015-07-28 2017-02-02 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel neisseria meningitidis serogroup y oligomer and process for synthesizing thereof
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
EP3506933A2 (en) 2016-09-02 2019-07-10 GlaxoSmithKline Biologicals SA Vaccines for neisseria gonorrhoeae
RS65362B1 (sr) 2016-09-02 2024-04-30 Sanofi Pasteur Inc Vakcina protiv neisseria meningitidis
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
WO2018173068A1 (en) * 2017-03-21 2018-09-27 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A novel synthetic neisseria meningitidis serogroup a oligomer and process for synthesizing thereof
CN120271939A (zh) 2019-09-05 2025-07-08 大金工业株式会社 组合物及其制造方法
CN115605222A (zh) 2019-09-27 2023-01-13 辉瑞公司（Us） 脑膜炎奈瑟氏菌组合物及其方法
GB202013262D0 (en) * 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
WO2025077785A1 (zh) * 2023-10-10 2025-04-17 康希诺生物股份公司 一种抗脑膜炎球菌的免疫组合物及其用途

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB408978A (en) 1932-10-22 1934-04-19 Zeiss Carl Improvements in instruments for measuring parallel coordinates
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
JPH04500203A (ja) 1988-08-25 1992-01-16 ザ　リポソーム　カンパニー，インコーポレイテッド インフルエンザワクチンおよび新規なアジュバント
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
KR920703114A (ko) 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
ATE439859T1 (de) 1990-08-23 2009-09-15 Univ North Carolina Transferrin bindende proteine aus neisseria- gonorrhoeae und neisseria-meningitidis. ihre verwendung in einem impfstoff
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
FR2682041B1 (fr) 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
DE122010000016I1 (de) 1992-05-23 2010-07-08 Glaxosmithkline Biolog Sa Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
CA2142981C (en) 1992-08-31 2007-10-23 Joseph Y. Tai Vaccines against group c neisseria meningitidis
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
DK0689454T4 (da) 1993-03-23 2005-05-30 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryl-lipid A
DE122009000058I1 (de) 1993-09-22 2009-12-31 Jackson H M Found Military Med Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
FR2734484B1 (fr) 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
WO1996040242A1 (en) 1995-06-07 1996-12-19 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
EP0833662B2 (en) 1995-06-23 2011-01-26 SmithKline Beecham Biologicals S.A. A vaccine composition comprsing a Haemophilus influenzae B polysaccharide conjugate antigen adsorbed onto aluminium phosphate
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
JP4472866B2 (ja) 1997-11-06 2010-06-02 カイロン ソチエタ ア レスポンサビリタ リミタータ ナイセリア抗原
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
SG152917A1 (en) 1998-01-14 2009-06-29 Chiron Srl Neisseria meningitidis antigens
AU759391B2 (en) 1998-02-12 2003-04-10 Wyeth Holdings Corporation Pneumococcal and meningococcal vaccines formulated with interleukin-12
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
EP1069910A1 (en) 1998-04-09 2001-01-24 GlaxoSmithKline Biologicals S.A. Adjuvant compositions
DK1093517T3 (da) 1998-05-01 2008-06-23 Novartis Vaccines & Diagnostic Neisseria-meningitidis-antigener og præparater
GB9810276D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
PT1741443E (pt) * 1998-05-29 2014-07-31 Novartis Vaccines & Diagnostic Combinação de vacinas para a meningite b/c
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
JP2004505885A (ja) 1998-08-19 2004-02-26 ノース　アメリカン　ワクチン，　インコーポレイテッド Ｎ−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体
BR9914374A (pt) 1998-10-09 2002-09-17 Chiron Corp Sequências genÈmicas de neisseria e métodos para seu uso
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
DK1163000T3 (da) 1999-03-19 2008-04-28 Glaxosmithkline Biolog Sa Vacciner imod antigener fra bakterier
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
EP1165796A2 (en) 1999-04-09 2002-01-02 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
NZ530640A (en) 1999-04-30 2006-06-30 Chiron S Conserved neisserial antigens
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CA2396871A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
JP4763210B2 (ja) 2000-02-28 2011-08-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ナイセリアのタンパク質の異種発現
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
KR100898845B1 (ko) * 2000-06-29 2009-05-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 다가 백신 조성물
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP1322656B1 (en) 2000-09-26 2008-01-16 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
YU66103A (sh) 2001-01-23 2006-05-25 Aventis Pasteur Vakcina multivalentnog konjugata meningokokalnog polisaharid-proteina
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CA2452720C (en) 2001-07-26 2012-04-17 Chiron S.R.L. Vaccines comprising aluminium adjuvants and histidine
US20050232936A1 (en) * 2001-07-27 2005-10-20 Chiron Corporation Meningococcus adhesins nada, app and orf 40
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
WO2003024480A2 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
ES2335979T3 (es) 2001-09-14 2010-04-07 Cytos Biotechnology Ag Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso.
US7838015B2 (en) * 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0129007D0 (en) * 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
ES2318117T3 (es) 2002-03-26 2009-05-01 Novartis Vaccines And Diagnostics S.R.L. Sacaridos modificados que tienen una estabilidad mejorada en agua.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
CA2489030A1 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
MXPA05003863A (es) 2002-10-11 2005-09-08 Chiron Srl Vacunas polipeptidicas para amplia proteccion contra lineas hipervirulentas de meningococos.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
JP4827726B2 (ja) * 2003-01-30 2011-11-30 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 複数の髄膜炎菌血清群に対する注射可能ワクチン
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ES2397923T3 (es) * 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos

Also Published As

Publication number Publication date
SI1670506T1 (sl) 2013-03-29
ATE506963T1 (de) 2011-05-15
CA2885040C (en) 2018-10-30
DE602004032481D1 (de) 2011-06-09
PL1961426T3 (pl) 2012-03-30
NZ546430A (en) 2009-04-30
PT1670506E (pt) 2013-01-28
JP2007507487A (ja) 2007-03-29
EP1961426B1 (en) 2011-04-27
SI1961426T1 (sl) 2011-10-28
RU2006114677A (ru) 2007-11-10
RU2009134033A (ru) 2011-03-20
RU2378010C2 (ru) 2010-01-10
AU2009200203A1 (en) 2009-02-12
BR122017002991B1 (pt) 2023-01-10
DK1670506T3 (da) 2013-02-25
BRPI0415025A (pt) 2006-12-12
US20150004191A1 (en) 2015-01-01
WO2005032583A3 (en) 2006-03-23
US9180204B2 (en) 2015-11-10
WO2005032583A2 (en) 2005-04-14
EP1670506A2 (en) 2006-06-21
HK1114784A1 (en) 2008-11-14
RU2595845C2 (ru) 2016-08-27
EP1670506B1 (en) 2012-11-21
CA2885040A1 (en) 2005-04-14
CA2540896C (en) 2015-06-02
US8765135B2 (en) 2014-07-01
EP1961426A1 (en) 2008-08-27
CA2540896A1 (en) 2005-04-14
US20080241180A1 (en) 2008-10-02
JP2011068698A (ja) 2011-04-07
ES2397923T3 (es) 2013-03-12
CY1113888T1 (el) 2016-07-27
PL1670506T3 (pl) 2013-04-30
DK1961426T3 (da) 2011-08-08
AU2004277758A1 (en) 2005-04-14
CN103357002A (zh) 2013-10-23
PT1961426E (pt) 2011-06-28
HK1087946A1 (en) 2006-10-27
CN103405761A (zh) 2013-11-27
JP4738339B2 (ja) 2011-08-03
JP5618842B2 (ja) 2014-11-05
EP2277538A1 (en) 2011-01-26
JP2014196362A (ja) 2014-10-16

Similar Documents

Publication Publication Date Title
CY1113522T1 (el) Συνδυασμενα εμβολια μηνιγγιτιδας
NO20033816L (no) Multivalent meningokokk polysakkarid-proteinkonjugat vaksine
CY2011001I2 (el) Εμβολια συνδυασμου για neisseria meningitidis
NO2017005I1 (no) Human pappilomavirus vaksine [type 6, 11, 16, 18, 31, 33, 45, 52, 58]
PT1777236T (pt) Sacáridos modificados possuindo estabilidade melhorada em água para utilização como um medicamento
PL2283857T3 (pl) Kompozycja szczepionki zawierająca skoniugowane natywne polisacharydy otoczkowe N. meningitidis
DK1596887T3 (da) Polymer-Faktor VIII-konjugat
CY1109582T1 (el) Συνδυασμενα μηνιγγοκοκκινα συζευγματα με κοινη πρωτεϊνη φορεα
GB0408977D0 (en) Immunising against meningococcal serogroup Y using proteins
MA29076B1 (fr) Préparations pharmaceutiques comprenant un dérivé de camptothécine
DK1797893T3 (da) Antistoffer mod phosphorylcholinkonjugater
ES1052161Y (es) Dispositivo homogeneizador batidor perfeccionado.
ATE398109T1 (de) 4-pyrimidinamine derivate, pharmazeutische zusammenstellungen und verwandte methoden
BRPI0412239A (pt) sistemas emulsificantes contendo derivados de azetidina
NO20026049D0 (no) Protein-basert vaksine mot meningokokk serogruppe W-135 sykdom
RU2003129138A (ru) Средство для устранения постнаркозной депрессии
ITBO20030116A1 (it) Dispositivo guida barra universale a smorzamento idraulico
ITRM20050220A1 (it) Cappello per divertimento azionato a motore.
ITMI20010524V0 (it) Dispositivo particolarmente studiato per fungere da contenitore-distributore per monete